刘晓慧,刘永红,张晓光,于 倩,魏雅楠.康复新液与他克莫司联合沙利度胺治疗口腔扁平苔藓的疗效及安全性分析[J].现代生物医学进展英文版,2020,(15):2971-2974. |
康复新液与他克莫司联合沙利度胺治疗口腔扁平苔藓的疗效及安全性分析 |
Efficacy and Safety of Kangfuxin Solution and Tacrolimus Combined with Thalidomide in the Treatment of Oral Lichen Planus |
Received:March 11, 2020 Revised:March 31, 2020 |
DOI:10.13241/j.cnki.pmb.2020.15.035 |
中文关键词: 他克莫司 康复新液 沙利度胺 口腔扁平苔藓 临床疗效 安全性 |
英文关键词: Tacrolimus Kangfuxin solution Thalidomide Oral lichen planus Clinical efficacy Safety |
基金项目:国家自然科学基金青年基金项目(81700948) |
Author Name | Affiliation | E-mail | LIU Xiao-hui | Department of Stomatology, Cangzhou Medical College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Cangzhou, Hebei, 061000, China | WangjunEvaxiangbao@163.com | LIU Yong-hong | Department of Stomatology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China | | ZHANG Xiao-guang | Department of Dermatology and Venereology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China | | YU Qian | Department of Stomatology, Cangzhou Medical College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Cangzhou, Hebei, 061000, China | | WEI Ya-nan | Department of Traditional Chinese Medicine, Cangzhou Medical College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Cangzhou, Hebei, 061000, China | |
|
Hits: 884 |
Download times: 515 |
中文摘要: |
摘要 目的:探讨康复新液与他克莫司联合沙利度胺治疗口腔扁平苔藓( oral lichen planus,OLP)的临床疗效及安全性。方法:选择2017年12月-2020年1月就诊于我院的80例OLP患者,采用随机数字表法将其分为联合组和对照组,每组40例。两组均进行常规治疗,对照组使用0.1 %的他克莫司软膏与康复新液治疗,联合组在对照组的基础上加用沙利度胺片,比较两组的临床疗效、治疗前后糜烂面大小、疼痛程度的变化以及不良反应的发生情况。结果:治疗后,联合组总有效率为90.00 %,显著高于对照组(72.5 %,P>0.05);与治疗前相比,两组口腔糜烂面积和疼痛程度均显著降低(P <0.05),且联合组口腔糜烂面积和疼痛程度显著低于对照组(P <0.05);治疗期间,对照组出现1例不良反应,具体表现为轻微的黏膜烧灼痛,停药后两天后症状消失,不良反应发生率为2.5 %,联合组出现2例不良反应,其中1例病变部位出现黏膜萎缩,1例出现色素沉着,不良反应发生率为5.0 %,两组不良反应的发生率比较无显著差异(P>0.05)。结论:康复新液与他克莫司联合沙利度胺治疗口腔扁平苔藓的临床疗效明显优于康复新液与他克莫司治疗,其能明显降低粘膜糜烂面积和疼痛程度,且安全性高。 |
英文摘要: |
ABSTRACT Objective: To investigate the clinical efficacy and safety of Kangfuxin solution and tacrolimus combined with thalidomide in the treatment of oral lichen planus. Methods: Eighty patients with OLP who were treated in our hospital from December 2017 to January 2020 were selected and divided into the combined group and the control group by a random number table method, with 40 cases in each group. Both groups were given routine treatment, the control group was treated with 0.1 % tacrolimus ointment and Kangfuxin solution, and the combined group was given thalidomide tablets on the basis of control group. The clinical efficacy, size of the eroded surface, degree of pain before and after treatment and the occurrence of adverse reactions were ompared between two groups. Results: After treatment, the total effective rate of combined group was 90.00 %, which was significantly higher than that of the control group (72.5 %, P>0.05). Compared with before treatment, the area of oral erosion and the degree of pain in botho groups were significantly reduced (P<0.05), which were significantly lower in the combined group than those of the control group (P<0.05). During the treatment period, one cases of adverse reaction was found in the control group, which was manifested as mild mucosal burning pain. The symptoms disappeared two days after the drug was stopped. The incidence of adverse reactions was 2.5 %. There were two cases of adverse reactions in the combined group, including 1 case of mucosal atrophy at the lesion site and 1 case of pigmentation, and the incidence of adverse reactions was 5.0 %. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The clinical efficacy of Kangfuxin solution combined with tacrolimus combined with thalidomide in the treatment of oral lichen planus was significantly better than that of Kangfuxin solution combined with tacrolimus, which could significantly reduce the mucosal erosion area and pain with high safety. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|